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COVID-19 AND LONG TERM CONDITIONS
Managing patients with rheumatic conditions during
the covid-19 pandemic
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Chronic rheumatic conditions are other long term conditions
that could be negatively affected by the covid-19 pandemic.1
Rheumatic diseases are among the most disabling diseases in
the world,2 and affected patients typically need to be strictly
followed to ensure a good quality of life and to maintain control
of disease activity. Moreover, patients with autoimmune chronic
arthritis (namely rheumatoid arthritis and seronegative
spondyloarthritis) are usually treated with immunosuppressant
drugs, which might impair their immune response and confer
an increased risk of infection.
Yet recommendations on how to manage patients with
autoimmune diseases, how to deal with anti-cytokine drugs used
by about 20% of these patients, and how to keep disease activity
under strict control in the context of covid-19 are all still lacking.
The mainstay for optimal chronic arthritis management is the
treat-to-target strategy, which involves frequent clinical
assessment of disease activity.3 How this could be performed
in the future needs rapid evaluation and response. Early
diagnosis and treatment are the main prognostic factors for
achieving clinical remission as well as halting radiographic
progression.4 “Early arthritis clinics” have been set up around
the world to shorten the delay between symptom onset and
diagnosis (and treatment). But these services are currently not
running properly, with all our efforts being focused on patients
with covid-19.
Rheumatologists should start thinking about the future of their
patients and start organising new ways to follow their patients
to avoid a major backwards step, losing all of the fantastic
clinical results obtained over the past 15 years.
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